Abstract
Excess production of proopiomelanocortin (POMC)-derived peptides with aldosterone-stimulating activity has been suggested to play a pathogenetic role in idiopathic hyperaldosteronism (IHA). To further investigate this issue, the opiate receptor antagonist naloxone was administered to 14 patients with primary aldosteronism, 6 with an aldosterone-producing adenoma (APA) and 8 with IHA. Clinical and hormonal effects of iv administration of naloxone (10 mg as a bolus) were compared with those obtained in 8 normal subjects. In normals as well as in APA and IHA patients, naloxone caused a significant increase in plasma cortisol, and no change in ACTH, plasma renin activity (PRA) and aldosterone levels. All subjects were retested after 2 mg dexamethasone. ACTH and cortisol were reduced and PRA was unchanged in all groups, without modifications after naloxone. Baseline aldosterone showed no significant changes in all groups. While normal subjects and APA failed to show any aldosterone response to naloxone after dexamethasone, IHA patients demonstrated a significant decrease, β-endorphin concentrations were in the normal range before and after dexamethasone. In conclusion, naloxone may have a direct action upon adrenal zona fasciculata increasing the cortisol responsiveness to physiological levels of ACTH in either normals or APA and IHA patients. The decrease of aldosterone induced by naloxone in IHA may be due to an intraadrenal opioid control of zona glomerulosa in this disorder.
Similar content being viewed by others
References
McCaa R.E., Young D.B., Guyton A.C., McCaa C.S. Evidence for a role of an unidentified pituitary factor in regulating aldosterone secretion during altered sodium balance. Circ. Res. 34(Suppl. 1): 1–15, 1974.
Matsuoka H., Mulrow P.J. β-lipotropin: a new aldosterone-stimulating factor. Science 209: 307, 1980.
Sen S.R., Valenzuela R., Smeby R., Bravo E.L., Bumpus F.M. Localization, purification, and biological activity of a new aldosterone-stimulating factor. Hypertension 3(Suppl. 1): 181, 1981.
Matsuoka H., Mulrow P.J., Franco-Saenz R., Li C.H. Stimulation of aldosterone production by β-melanotropin. Nature 291: 155, 1981.
Smith T., Grossman A., Gaillard R., Clement-Jones V., Ratter S., Mallinson J., Lowry P.J., Besser M., Rees L. Studies on circulating met-enkephalin and beta-endorphin: normal subjects and patients with renal and adrenal disease. Clin. Endocrinol. (Oxf.) 15: 291, 1981.
Schiffrin E.L., Chretien M., Seidah N.G., Lis M., Gutkowska J., Cantin M., Genest J. Response of human aldosterenoma cells in culture to N-terminal-glycopeptide of pro-opiomelanocortin and γ 3-MSH. Horm. Metab. Res. 15: 181, 1983.
Rabinowe A.L., Taylor T., Dluhy R.G., Williams G. β-endorphin stimulates plasma renin and aldosterone release in normal human subjects. J. Clin. Endocrinol. Metab. 60: 485, 1985.
Griffing G.T., Mclntosh T., Berelowitz B., Hudson M., Salzman R., Manson J.A.E., Melby J.C. Plasma β-endorphin levels in primary aldosteronism. J. Clin. Endocrinol. Metab. 60: 315, 1985.
Griffing G.T., Berelowitz B., Hudson M., Salzman R., Manson J.A.E., Aurrechia S., Melby J.C., Pedersen R.C., Brownie A.C. Plasma immunoreactive gamma melanotropin in parents with idiopathic hyperaldosteronism, aldosterone-producing adenomas, and essential hypertension. J. Clin. Invest. 76: 163, 1985.
Eipper B.A., Mains R.E. Structure and biosynthesis of proadrenocorticotropin/ endorphin and related peptides. Endocr. Rev. 1: 1, 1980.
Lowry P.J. The “two-site” immunoradiometric assay. In “Endorphins: assay and physiological significance”, Workshop organized by the European Programme of Research on Breakdown in Adaptation, Liège, May 30–31, 986 (Abstract). Horm. Res. 25: 234, 1987.
Stockigt J.R., Collins R.D., Biglieri E.G. Determination of plasma renin concentration by angiotensin I immunoassay: diagnostic importance of a precise measurement of subnormal renin in hyperaldosteronism. Circ. Res. 28(Suppl. 2): 175, 1971.
Volavka J., Cho D., Mallya A., Bauman J. Naloxone increases ACTH and cortisol levels in normal man. N.Engl. J. Med. 300: 1056, 1979.
Morley J.E., Baranetsky N.G.,Wingert T.D., Carlson H.E., Hersham J.H., Melmed S., Levin S.R., Jalison K.R., Weizman R., Chang R.J., Varner A.A. Endocrine effects of naloxone-induced opiate receptor blockade. J. Clin. Endocrinol. Metab. 50: 251, 1980.
Grossman A., Moult P.J., Cunnah D., Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotropin release in man. Neuroendocrinology 42: 357, 1986.
Gaillard R.C., Grossman A., Smith R., Rees LH., Besser G.M. The effect of met-enkephalin analog on ACTH, β-endorphin and met-enkephalin in patients with adrenocortical disease. Clin. Endocrinol. (Oxf.) 14: 471, 1981.
Leslie R.D.G., Prescott R.W.G., Kendall-Taylor P., Cook D., Weightman D., Ratcliffe J.O., Ingram M.C. Opiate receptor blockade and diurnal pituitary and adrenal hormone levels. Horm. Metab. Res. 17: 86, 1985.
Fallo F., Boscaro M., Sonino N., Mantero F. Effects of naloxone on the pituitary-adrenal axis in patients with dexamethasone-suppressible hyperaldo-steronism. Clin. Endocrinol. (Oxf.) 26: 163, 1986.
Racz K., Glaz E., Kiss R., Lada G., Varga I., Vida I., Di Gleria K., Medzihradszky K., Lichtwald K., Vecsei P. Adrenal cortex-a newly recognized peripheral site of actions of enkephalins. Biochem. Biophys. Res. Commun. 97: 1346, 1980.
Lymangrover J.H., Dokas L.A., Kong A., Martin R., Saffran M. Naloxone has a direct effect on the adrenal cortex. Endocrinology 109: 1132, 1981.
Saito E., Ichigawa Y., Homma M. Direct inhibitory effect of dexamethasone on human adrenal “in vivo”. J. Clin. Endocrinol. Metab. 48: 861, 1979.
Güllner H.G., Nicholson W.E., Gill J.E., Orth D.N. Plasma immunoreactive proopiomelanocortin-derived peptides in patients with primary aldosteronism, idiopathic hyperaldosteronism with bilateral adrenal hyperplasia, and dexamethasone-suppressible hyperaldosteronism. J. Clin. Endocrinol. Metab. 59: 853, 1983.
Bramnert M., Hokfelt B. Lack of effect of naloxone in a moderate dosage on the exercise-induced increase in blood pressure, heart rate, plasma catecholamines, plasma renin activity and plasma aldosterone in healthy males. Clin. Sci. 68: 185, 1985.
Lymangrover J.H., Keku E., Eldridge J.C. Naloxone potentiates ACTH and angiotensin but not potassium stimulated aldosterone secretion. Life Sci. 33: 1605, 1983.
Kalin N.D., Risch S.C., Cohen R.M., Insel T., Murphy D.L. Dexamethasone fails to suppress β-endorphin plasma concentrations in humans and rhesus monkeys. Science 209: 827, 1980.
Gross M.D., Grekin R.J., Gniadek T.C., Villareal J.Z. Suppression of aldosterone by cyproheptadine in idiopathic hyperaldosteronism. N.Engl. J. Med. 305: 181, 1981.
Evans J.E., Erdelyi E., Weber E., Barchas J.D. Identification of pro-opiomelanocortin derived peptides in the human adrenal medulla. Science 221: 957, 1983.
Imura H., Nakai Y., Nakao K., Oki S., Tanaka I., Jingami H., Yoshimasa T., Tsukada T., Ikeda Y., Suda M., Sakamoto M. Biosynthesis and distribution of opioid peptides. J. Endocrinol. Invest. 6: 139, 1983.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fallo, F., Boscaro, M., Sonino, N. et al. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. J Endocrinol Invest 11, 261–265 (1988). https://doi.org/10.1007/BF03350149
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350149